Introduction
The challenge of this study is to suggest a new multitarget and regenerative approach disclosing new perspectives in neurodegenerative diseases. "Regenerative medicine" may provide an innovative treatment for many human disorders by the use of stem cells (SC). SC are a unique population of cells able to selfrenew and differentiate into different cell types 1 and they can be transplanted or manipulated in vivo to restore missing cells. Therefore, considering the capability of self-renewal and differentiation into a range of tissues of Neural Stem Cells (NSCs), SC-mediated therapy can be considered, at the present, the goal in cell replacement therapies in different pathological conditions such as in inammation, neurodegeneration, immunomodulation and stimulation of endogenous recovery. Several reports demonstrated the expression of some ATPbinding cassette (ABC) transporters such as P-glycoprotein (P-gp, ABCB1) and Breast Cancer Resistance Protein (BCRP, ABCG2) in human neural stem/progenitor cells (hNSPCs).
2,3
Moreover, the importance of ABC transporter expression and localization in NSCs on their differentiation and proliferation has been highlighted. 2 Indeed, P-gp and BCRP expression represents a feature of proliferating stem cells and not of quiescent cells and their activities are involved in tissue regeneration mechanism, and in the protection from cell death under stress conditions.
2
During the early developmental step, embryonic stem cells need a "protective barrier" due to the presence of ABC transporters pivotal in maintaining SC in an undifferentiated state; by contrast, their downregulation may induce an increased differentiation of NSCs. 2 Indeed, Blood-Brain Barrier (BBB) endothelial cells produce soluble factors inuencing the differentiation of NSPCs and in physiological conditions these factors, as substrates of ABC pumps, are effluxed by these transporters. When the expression of these proteins decreases, as in the early stage of Alzheimer's Disease (AD), these factors are not effluxed altering the microenvironment of stem cell niche and cellular homeostasis with functional alterations in neurogenesis.
1 Therefore, since the expression of ABC transporters present in hNSPCs can be modulated, these proteins are the key for promoting hNSPCs self-renewal without differentiation. This link existing between ABC transporters present in NSCs can explain the potential of NSCs as therapeutic strategy in several brain disorders such as AD, Parkinson and Huntington's diseases through an endogenous activation. Moreover, an additional target identied in the early stage of AD is represented by Toll-Like Receptor 4 (TLR4); 4, 5 it is widely reported that microglia activation via TLR4 is closely associated to a number of neurodegenerative disorders including AD and ischemic stroke. 6 In the senile plaques observed in the brain of AD patients, microglia is present in an activated state, and it is considered important in the pathogenesis of the disease. Microglia activation results in the overproduction of NO, oxygen free radicals, proteases, adhesion molecules and pro-inammatory cytokines responsible for the degenerative process.
7 AD patients and AD animal models display increased expression of CD14 (a co-receptor for TLR4), TLR4 and TLR2 8 in response to the presence of Ab and TLR4 mutation induces a decreased microglial activation, an increase in Ab deposits and exacerbation of cognitive decits. 4 Therefore, as Ab deposits occur, microglia is activated via TLR4 signaling to block Ab deposition and to preserve cognitive functions from Ab-mediated neurotoxicity.
9 On the basis of these evidences, microglia activation via TLR4 in early stages of AD pathogenesis exerts a neuroprotective effect, and TLR4 pathways may be considered a potential therapeutic targets.
With all these aspects in mind, we hypothesized a multitargets drug, TLR4 inducer and P-gp/BCRP upregulating agent, simultaneously able to protect neurons by AD progression and in the meantime to activate the neuroreparative steps by maintaining stem cells in undifferentiated state. By a large screening of our P-gp/BCRP ligands library, we selected a small molecule named MC111. 10 MC111 prole has been deepened and the following activities have been studied: (i) the inuence on TLR4 signaling; (ii) the activity towards P-gp and BCRP; (iii) the effect on neurites sprouting.
Results
MC111 inuence on TLR4 signaling and on P-gp and BCRP expression MC111 was found able to increase TLR4 and P-gp expression (Fig. 1A ) in SW480 human colon adenocarcinoma cells; TLR4 involved pathway has been deeply studied considering also the effect on other targets such as the nuclear factor NF-kB. TLR4 pathway involves the activation of NF-kB, as depicted in Fig. 1B ; in unstimulated cells, NF-kB is sequestered in cytoplasm as inactive form by interacting with inhibitor of NF-kB (IkB) proteins. TLR4 stimulation by ligands leads to IkB phosphorylation with the release of NF-kB in the nucleus leading to the transcription of many pro-inammatory genes encoding cytokines. In order to verify the existence of a link between ABCB1-TLR4 and MC111 activity, as depicted in Fig. 1C , P-gp (ABCB1) has been silenced and TLR4 expression detected in the presence of MC111; the ligand activity on P-gp expression has been evidenced aer TLR4 silencing. The experiments demonstrated that MC111 activity on TLR4 and P-gp was reciprocally dependent from the expression of the two proteins.
Moreover, also MC111 activity prole towards BCRP has been investigated in MCF7 cells where BCRP, but not P-gp, is highly expressed.
MC111 activity towards P-gp and BCRP
To assess how the expression and the activity of these proteins is inuenced by MC111, the molecule has been probed in three cell lines (MCF7, hCMEC/D3 and Colo320 cells) in presence of radiolabeled P-gp and BCRP substrates, [ 3 H]verapamil and [
11
C] MC150, respectively (unpublished results, formula depicted in supplementary materials). The substrates verapamil and MC150 are differently radiolabelled since verapamil is commercially available while MC150, belonging to our library, has been radiolabelled for in vivo PET analysis (studies in progress). The results demonstrated that MC111 increased the efflux of both substrates conrming that our ligand is an inducer of expression and also activity of the two pumps.
The immunostaining analysis on MCF7 cells demonstrated an increased BCRP expression already aer 2 hours of MC111 exposition. In hCMEC/D3 cells, the same effect on BCRP expression was found aer 72 h treatment with MC111.
The inuence of MC111 on P-gp activity was assessed by subcellular fractionation experiments in Colo320 cells where the protein is highly present. In the presence of MC111, an increased [
3 H]verapamil efflux was observed. Moreover, also the efflux of a P-gp/BCRP radiolabeled substrate ([ 11 C]-MC150) was increased by MC111 pre-treatment in Colo320 cells indicating induced BCRP activity.
Neuroregeneration
We investigated the role of MC111 on dissociated primary sensory neurons with particular emphasis on the neurite growth changes. The effects of MC111 on Dorsal Root Ganglion (DRG) neurons in comparison to those cultured in a basic culture medium in the absence of NGF (negative control) or in the presence of NGF (positive control) was studied. 11 DRG neurons culture was carried out following 3 different experimental conditions: Bottenstein and Sato's Medium (BSM) alone; BSM + 1 mg ml À1 NGF and BSM + 1 mM MC111. Neurite outgrowth from DRG living neurons aer 72 h culture was observed under phase contrast microscope and images of the cells were digitized ( Fig. 2A-F) . From a qualitative analysis of the coverslips it appeared, that few cells cultured in BSM alone sprouted neurites ( Fig . Subsequent quantitative analysis of the DRG neurons was performed. Four parameters were measured: (1) % of cells containing neuritis respect to cells without neurites that resulted: 30% AE 8.7 (only BSM); 52% AE 3.5 (BSM + NGF); 59% AE 7.1 (BSM + MC111) (Fig. 3A) . These results pointed out that both NGF and MC111 treatments induced a signicant increase (P < 0.01) of neurons sprouting neurites in comparison to control. (2) Length of longest neurite: signicant differences are evident between control neurons and neurons treated either with NGF or MC111; the length of the longest neurite was indeed similar between neurons treated with NGF or MC111 (Fig. 3B) . (3) The number of neurites/cell: 1.6 AE 0.9 (only BSM); 8 AE 2.6 (BSM + NGF); 2.2 AE 0.8 (BSM + MC111). Only treatment with NGF was effective in inducing a signicantly higher number of neurites respect to the control (Fig. 3C) . (4) Total neurite length: 884 AE 467 mm (only BSM); 4848 AE 1363 mm (BSM + NGF); 2116 AE 494 mm (BSM + MC111). Both NGF and MC111 induced a signicant increase in the sum of the total neurite length, that was indeed higher in the presence of NGF (Fig. 3D) .
These results show that MC111 induces a relevant neurite sprouting with respect to the negative control but with different characteristics compared to NGF. Following treatment with NGF, a signicant increase in total neurite number developed from each neuron was detected. The effect of MC111 was mainly represented by a moderate increase in neurite number and a great increase in the percentage of neuron spouting neurites with respect to the total neuron number, comparable with the increase obtained in the presence of NGF. The morphology of neurite sprouting from cells treated with MC111 is more similar to the physiological one, i.e. originating from the cellular body, that divides into two neurites (Fig. 2C, F, I and L). The observation that MC111 induces the growth of fewer but longer neurites in comparison to NGF, deserves particular attention in the perspective of peripheral nerve regeneration and repair (Fig. 4) .
Experimental
Materials and method MC111 inuence on TLR4 signaling and on P-gp and BCRP expression Cell cultures. To explore how MC111 inuences TLR4 signaling we used SW480 cells since they express P-gp and can signal through TLR4. 12 The human colon adenocarcinoma cell line SW480 (ICLC HTL99017-Interlab Cell Line Collection) was cultured on Leibovitz-15 medium supplemented with 10% fetal bovine serum, 100 U ml À1 penicillin, 100 mg ml À1 streptomycin and L-glutamine (2 mM; Life Technologies-Invitrogen).
Cultures were maintained at 37 C in a humidied atmosphere containing 5% CO 2 and expanded in tissue culture asks (75 cm 2 ; BD Biosciences), changing daily the medium.
The cells were seeded in six-well cell culture plates at 5 Â 10 5 cells per well and cultured to reach 80% conuency. Cell treatments. Cell cultures were treated with lipopolysaccharide (LPS) from Salmonella typhimurium (Sigma-Aldrich) or with MC111 (concentration ranging from 500 nM to 250 mM). Preliminary experiments were performed in order to establish the optimal dose (1 mg ml À1 ) of LPS and MC111 (250 mM) and time of exposure to LPS (48 h). Untreated cells were used as control.
Treatment of cell cultures with small interfering RNA. Cell cultures (60-70% conuence) were submitted to P-gp or TLR-4 specic small interfering RNA (siRNA) using commercial kits (Santa Cruz Biotechnology) according to the manufacturer's protocol. Cells were incubated with 60-80 pmols of siRNA for 5-7 h at 37 C, using a transfection reagent. Then, 1 ml of complete medium (2Â) was added and cells incubated for 24 h. The day aer, medium was replaced with fresh culture medium and cells were incubated for 48 h before experimental treatments. Aer this time, cells were submitted to LPS or MC111 treatment as indicated above.
Electrophoresis. Aer treatment as previously described, cells were washed twice in PBS, detached with ice-cold PBS, collected and centrifuged at 600g for 10 min. The supernatant was removed and the pellet was harvested and lysed by ice-cold lysis [1% (v/v) Triton X-100, 20 mM Tris-HCl, 137 mM NaCl, 10% (v/v) glycerol, 2 mM EDTA, 1 mM phenylmethylsulfonyl uoride Western blotting. Aer electrophoresis, the resolved proteins were transferred from the gel to nitrocellulose membranes using iBlot Dry Blotting System A (Life-TechnologiesInvitrogen). Then, membranes were blocked by PBS, (pH 7.2) containing 0.1% (v/v) Tween 20 and 5% (w/v) non-fat dried milk for 1 h and washed three times with 0.1% Tween 20-PBS (T-PBS). Specic proteins were detected using optimal concentration of primary antibodies, rabbit polyclonal anti human TLR-4 (1 : 200) or mouse monoclonal anti-human P-glycoprotein (MDR) (1 : 500). The binding of antibodies was detected with horseradish peroxidase (HRP)-conjugated goat anti-rabbit IgG followed by chemiluminescence detection (Pierce, Perbio, Rockford, USA). The b-actin protein level was used as a protein loading control in western blotting. Densitometric analysis. The visualized bands obtained aer immunoblotting experiments, were submitted to densitometric analysis using id image analysis soware (Kodak Digital Science). b-actin was used for normalization of the immunoblotting products. Results were expressed as relative protein expression to b-actin.
Statistical analysis. Results were statistically examined by analysis of variance (one-way ANOVA) and a p-value < 0.05 was considered statistically signicant.
MC111 activity on P-gp and BCRP. Commercially available chemicals were purchased from Sigma-Aldrich. Cell lines. The colon cancer cell line of human origin, Colo320 and the human breast adenocarcinoma, MCF-7 (both kindly provided by the Medical Oncology Department of the UMCG, Netherlands) were cultured in Roswell Park Memorial Institute (RPMI) 1640 medium supplemented with fetal calf serum (10%) in a humidied incubator at 37 C, 5% CO 2 atmosphere. The cerebral microvascular endothelial cells of human origin, hCMEC/D3 (supplied by Institut Cochin, Paris, France), were cultured in RPMI 1640 supplemented with 10% fetal calf serum (FCS) Fetal Calf Serum (10%), penicillin (1%), hydrocortisone (1.4 mM), acid ascorbic (5 mg ml À1 ), HEPES (10 mM), bFGF (1 ng ml À1 ) in a humidied incubator at 37 C, 5% CO 2 atmosphere.
The glioma cell line of rat origin C6 was cultured in Dulbecco's Modied Eagle Medium (DMEM) supplemented with 10% FCS in a humidied incubator at 37 C, 5% CO 2 atmosphere. Twice a week, the cells were harvested with trypsin and medium was changed.
Immunostaining of hCMEC/D3 and MCF7 cells. hCMEC/D3 or MCF7 cells were grown on gelatin-coated glass coverslips and exposed to MC111 for 24 and 72 h. Aer washing with cold PBS, cells were blocked with 1% PBS-BSA for 15 minutes; xed with 4% paraformaldehyde (PFA) for 20 minutes; permeabilized with 0.2% Triton-X-100 for 10 minutes and blocked with 1% PBS-BSA for 15 minutes. The cells were incubated with 1% primary anti-P glycoprotein antibody or primary anti-BCRP/ABCG2 antibody in 1% PBS-BSA for 1 hour. The cells were then blocked in 15 minutes in 1% PBS-BSA and incubated in the dark with 0.02% secondary antibody for P-gp or BCRP for 30 minutes. Nuclear localization was also determined by staining with 1 mg ml À1 of DAPI. In between steps, the cells were washed 3 times with PBS. The expression of proteins was visualized by Leica DM6000B uorescence microscope. Subcellular fractions for detecting fraction-specic inducer uptake. Subcellular fractionation was performed at different concentration of inducer (5-300 mM) to establish the minimum concentration to reach the maximum uptake of
Aerwards, this concentration was used to perform subcellular fractionation at different time points (20 min to 24 hours). The protocol for subcellular fractionation available on the website of Abcam®, https://www.abcam.com, was modied. At the time of use, 25 ml of stock subcellular fractionation buffer were taken and 25 ml of 1 mM dithiothreitol and 125 ml of protease inhibitor cocktail were added. The cells were treated with MC111 in a concentration range of 5-300 mM followed by addition of 0.2 ml [ 3 H]verapamil (0.2 mCi). Aer 30 min incubation the medium was removed and the cells were harvested from the plate using trypsin and transferred into clean Eppendorf tubes containing RPMI 1640 medium for neutralizing the trypsin. To obtain the cell pellet, the cell suspension was centrifuged at 9000 rpm for 2 min. Supernatant was discarded and 500 ml of cold subcellular fractionation buffer was added to each cell pellet. Pellets were homogenized using 25 G needle and 1 ml syringe, distinct for each pellet, and kept on ice for 20 minutes. Aer homogenization, the suspension was centrifuged at 2500 rpm for 5 min. The supernatant was transferred into vials for liquid scintillation and counted on a g-counter (cytoplasm fraction). 500 ml of the buffer was added to the cell pellet which was vortexed for 5 seconds, kept on ice for 10 minutes and centrifuged at 8000 rpm for 5 min. The supernatant was transferred into vials for liquid scintillation and was counted on a g-counter (membrane fraction). The remaining pellets were also counted by liquid scintillation. was added in the apical compartment following the addition of MC111 to yield a nal concentration of 150 mM in the apical side. The cells were incubated at 37 C at different times. Aer the incubation period, the medium from each side was removed and transferred to vials for liquid scintillation and samples were counted on a g-counter. The ratio of apical to basolateral was calculated.
The chemistry and biology of this compound is already reported in our previous paper.
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Neuroregeneration DRG neuron harvest. The animal experiments were performed according to the European Community guidelines for care and use of animals. In particular animals were housed in airconditioned room with 12/12 h dark-light cycle, with food and water ad libitum, in the approved facility at the University of Bari. All animal procedures were performed in accordance with the Guidelines for Care and Use of Laboratory Animals of the "University of Bari (OPBA di Ateneo)" and the Italian Ministry of Health. Adult male Sprague-Dawley rat (age of 6-8 months) was anaesthetized by isourane before decapitation and the dorsal root ganglia (DRG) were gently pulled by its roots and harvested from all accessible levels using ne forceps. DRG were collected and placed on a Petri dish containing Ham's F12 medium at room temperature. The surrounding connective tissue and nerve roots of the DRG were removed under the microscope. Dissociated sensory neurons, from one rat for each assay, were prepared as previously reported.
14 The DRG neurons were seeded on glass coverslips in 24 well plates pre-coated with 2 mg ml À1 laminin in modied Bottenstein and Sato's Medium (BSM; F12 medium containing 100 mM putrescine, 30 nM sodium selenite, 20 nM progesterone, 1 mg ml À1 BSA, 0.1 mg ml À1 transferrin, 0.01 mM cytosine arabinoside and 10 pM insulin). Aer 2 h BSM incubation (negative control), BSM supplemented with either NGF 1 mg ml À1 or MC111 1 mM was added to DRG culture which was incubated at 37 C, 5% CO 2 for 72 h. Immunocytochemistry. Before immunostaining, living cells were examined and photographed under a Nikon DIAPHOT TS-100 microscope. Images were digitized with Â20 objective and a Nikon Digital Video Camera E995 (Coolpix 995). Subsequently the DRG neurons were xed with 4% (w/v) PFA/PBS solution for 30 min at RT. Aer three PBS washes, the cells were permeabilized in 0.02% Triton X-100/PBS for 20 min. The cells were then incubated with 5% normal horse serum (NHS) (Vector Labs Inc.) for 1 h at RT to block non-specic binding sites. The blocking solution was replaced with PBS containing primary monoclonal mouse anti-bIII-tubulin antibody (Cell Signaling Technology) at 1 : 1000 dilution for 24 h at 4 C. The cells were nally incubated with secondary FITC horse anti-mouse antibodies at 1 : 100 dilution (Vector Lab Ltd, UK) for 1 h at RT. The coverslips were mounted with Vectashield on glass microscope slides. Fluorescence was detected by an inverted Zeiss Axiovert 200 microscope equipped with epiuorescence. Cells were imaged with CoolSNAP HQ CCD camera (Roper Scientic, Trenton, NJ) using Metamorph soware (Universal Imaging Corp., Downingtown, PA).
Neurite outgrowth analysis. Five independent culture experiments were carried out. Images of eight elds per well were taken. The number of cells sprouting neurites was determined by examining the eld and counting cells with at least one neurite equivalent to the length of a cell body diameter. This number was expressed as a percentage of the total number of cells in the eld. 8 bit images were loaded into ImageJ (version 1.47) and individual neurons, immunostained with anti-bIII-tubulin as described above, were manually traced with NeuronJ plugin (version version 1.4.2).
15, 16 The following parameters were analyzed: (1) % of sensory neurons spouting neuritis respect to all the sensory neurons present on the eld; (2) length of longest neurite; (3) total number of processes grown in each eld from all sensory neurons; (4) the total neurite length from all neurons in the eld. Statistical analysis used to compare data from different groups was performed by Student's t-test. Values of p less than 0.05 or 0.01 were considered statistically signicant.
Conclusions
Neuroprotection and neuroreparative activities could be considered the two different faces of same medal where MC111 is the cohesive element. It represents a modern and smart drug able to hit different and synergistic targets of neurodegenerative pathways (TLR4, P-gp and BCRP induction) and exerts neuroregenerative effect although the molecular mechanism of the last should be investigated. Another important advantage of these results is that MC111 is the rst small molecule able to give these combined effects and further its lead optimization is easy to carry out because of the simple structure of the ligand.
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